Liposomes for cardiovascular targeting
| Autor: | William C. Hartner, Vladimir P. Torchilin, Tatyana S. Levchenko |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Chemistry
Pharmaceutical Drug Compounding Pharmaceutical Science Pharmacology Antibodies Polyethylene Glycols Drug Stability In vivo medicine Animals Humans Technology Pharmaceutical Liposome business.industry Biological Transport Cardiovascular Agents Lipids In vitro Molecular Imaging medicine.anatomical_structure Cardiovascular Diseases Liposomes Circulation time business Ex vivo Blood vessel |
| Zdroj: | Therapeutic Delivery. 3:501-514 |
| ISSN: | 2041-6008 2041-5990 |
| DOI: | 10.4155/tde.12.18 |
| Popis: | Liposome-based pharmaceuticals used within the cardiovascular system are reviewed in this article. The delivery of diagnostic and therapeutic agents by plain liposomes and liposomes with surface-attached targeting antibodies or polyethylene glycol to prolong their circulation time and accumulation at vascular injuries, ischemic zones or sites of thrombi are also discussed. An overview of the advantages and disadvantages of liposome-mediated in vitro, ex vivo and in vivo targeting is presented, including discussion of the targeting of liposomes to pathological sites on the blood vessel wall and a description of liposomes that can be internalized by endothelial cells. Diagnostic liposomes used to target myocardial infarction and the relative importance of liposome size, targetability of immunoliposomes and prolonged circulation time on the efficiency of sealing hypoxia-induced plasma membrane damage to cardiocytes are discussed as a promising approach for therapy. The progress in the use of targeted liposomal plasmids for the transfection of hypoxic cardiomyocytes and myocardium is presented. Stent-mediated liposomal-based drug delivery is also reviewed briefly. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|